Where are we with RSV prophylaxis?

Archives of Disease in Childhood: Education and Practice Edition

Volumn 101, Issue 1, 2016, Pages 38-42

  Caldwell, Neil A ^a   Townsend, Ceri ^b  

^a ARROWE PARK HOSPITAL   (United Kingdom)

^b WIRRAL UNIVERSITY TEACHING HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT;

ARTICLE; CHILDHOOD MORTALITY; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOTHERAPY; LOWEST INCOME GROUP; MORTALITY; PARENTAL SMOKING; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK REDUCTION; SEASONAL VARIATION; SINGLE DRUG DOSE; SOCIAL CLASS; DRUG EFFECTS; FEMALE; IMMUNIZATION; INFANT; MALE; NEWBORN; PATHOPHYSIOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTOR;

ANTIVIRAL AGENTS; FEMALE; HUMANS; IMMUNIZATION; INFANT; INFANT, NEWBORN; MALE; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RISK FACTORS;

EID: 84955478717     PISSN: 17430585     EISSN: 17430593     Source Type: Journal    
DOI: 10.1136/archdischild-2015-308780     Document Type: Article

References (16)

1. Shelley PB. Ode to the west wind. In Prometheus unbound. A lyrical drama in four acts, with other poems. London: C and J Ollier, 1820.
2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory tract infections due to respiratory syncytial virus in young children: a systematic review and meta-Analysis. Lancet 2010;375:1545-55.
3. Public Health England. Respiratory syncytial virus. Green Book Chapter 27a, Respiratory syncytial virus. http://www.gov.uk/government/organisations/public-health-england/series/immunisation-Against-infectious-disease-the-green-book
4. Hall CB, Douglas RG, Geiman JM. Possible transmission by fomites of respiratory syncytial virus. J Infect Dis 1980;141: 98-102.
5. Simoes EAF. Respiratory syncytial virus infection. Lancet 1999;354:847-52.
6. Bracht M, Basevitz D, Cranis M, et al. Strategies for reducing the risk of respiratory syncytial virus infection in infants and young children: a Canadian nurses' perspective. Neonatal Netw 2012;31:357-68.
7. Andabaka T, Nickerson JW, Rojas-Reyes MX, et al. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 2013;4:CD006602, 1469-493X.
8. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker CJ, Kimberlin DW, et al. eds. Red book: 2012 report of the committee on infectious diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2012:609-18.
9. National Institute for Health and Care Excellence. Bronchiolitis: diagnosis and management of bronchiolitis in children. (Clinical guideline ng9). 2015. http://www.nice.org. uk/guidance/ng9
10. Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child 2003;88:1065-9.
11. Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124: 1694-701.
12. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidelines for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014;134:415-20.
13. SPC for Synagis, https://www.medicines.org.uk/emc/medicine/5676 (accessed 12 Jul 2015).
14. Paediatric Formulary Committee. BNF for children [2014-2015]. London: BMJ Group, Pharmaceutical Press, and RCPCH Publications, 2015.
15. Mullins JA, Lamonte AC, Bresee JS, et al. Substantial variability in community respiratory syncytial virus season timing. Pediatr Infect Dis J 2003;22:857-62.
16. WHO Consultation on respiratory syncytial virus (RSV) vaccine development 23-24 March 2015, Starling Hotel and Conference Center http://www.who.int/immunization/research/meetings-workshops/rsv-vaccine-development/en/